We expanded GWAS discovery for type 2 diabetes (T2D) by combining data from 898,130 European-descent individuals (9% cases), after imputation to high-density reference panels. With these data, we (i) extend the inventory of T2D-risk variants (243 loci, 135 newly implicated in T2D predisposition, comprising 403 distinct association signals); (ii) enrich discovery of lower-frequency risk alleles (80 index variants with minor allele frequency < 5%, 14 with estimated allelic odds ratio > 2); (iii) substantially improve fine-mapping of causal variants (at 51 signals, one variant accounted for > 80% posterior probability of association (PPA)); (iv) extend fine-mapping through integration of tissue-specific epigenomic information (islet regulatory annotations extend the number of variants with PPA > 80% to 73); (v) highlight validated therapeutic targets (18 genes with associations attributable to coding variants); and (vi) demonstrate enhanced potential for clinical translation (genome-wide chip heritability explains 18% of T2D risk; individuals in the extremes of a T2D polygenic risk score differ more than ninefold in prevalence).
A rray-based genome-wide association studies (GWAS) have identified ~140 loci influencing the risk of T2D [1] [2] [3] . Follow-up of these genetic discoveries has been compromised by the incomplete coverage of the most frequently used genotyping arrays, the imperfect performance of the reference panels available for imputation, extensive local linkage disequilibrium (LD), and inadequate sample sizes. These factors together have limited the power to detect low-frequency alleles with population-scale effects, to deliver clinically relevant risk prediction, and to define molecular mechanisms involved in disease predisposition. Here, we address the limitations of previous studies by combining GWAS from ~900,000 Europeans with dense, high-quality imputation, producing the most comprehensive view to date of the genetic contribution to T2D with respect to locus discovery, causal-variant resolution, and mechanistic insight.
Results
Study overview. We combined data from 32 GWAS, including 74,124 T2D cases and 824,006 controls of European ancestry. The effective sample size (N eff ) of 231,436 represents a 3.2-fold increase in N eff relative to the largest previous genome-wide study of T2D risk in Europeans 1 . After harmonized quality control, 31 of the 32 GWAS were imputed using 64,976 whole-genome-sequenced haplotypes from the Haplotype Reference Consortium (HRC) 4 : the exception was the deCODE GWAS, which was imputed with a population-specific reference panel of 30,440 Icelandic haplotypes 5 (Methods and Supplementary Table 1) . We conducted T2D-association analyses with and without adjustment for body-mass index (BMI).
Discovery of novel loci for T2D susceptibility. We tested for T2D association with ~27 million variants passing quality-control filters, ~21 million of which had a minor allele frequency (MAF) < 5%. Our meta-analysis identified variants at 231 loci reaching genomewide significance (P < 5 × 10 Table 2) .
Among samples not included in previous discovery efforts (42,734 cases and 497,261 controls), we replicated associations (directionally consistent, P < 0.05) at 126 of 140 previously reported T2D loci, including all 106 regions first discovered in Europeanonly or transancestry efforts 3, [6] [7] [8] and 20 initially reported in studies of non-European individuals 9, 10 . The 14 loci not replicated were all first identified in non-European-ancestry samples: at five, the reported lead variant had MAF < 1% in Europeans.
Multiple association signals at T2D-susceptibility loci. Across the 243 associated loci, we identified 160 additional signals at 'locuswide' significance (P < 10 −5
; Methods), 110 of which were within previously reported T2D loci. Overall, we observed one signal at 151 loci, and two to ten signals at the remaining 92 loci (Supplementary  Table 2 ), for a total of 403 distinct T2D-association signals.
We observed the first evidence for multiple signals at the TCF7L2 locus. In addition to rs7903146, the largest-effect common-variant signal for T2D in Europeans, we detected seven secondary signals, each represented by noncoding index variants (0.5% < MAF < 47.6%, 1.05 < odds ratio (OR) < 1.36).
In the ~1-Mb telomeric region of chromosome 11 that encompasses the (previously annotated) INS-IGF2 and KCNQ1 loci, we detected 15 distinct signals (0.15% < MAF < 42.8%, 1.03 < OR < 1.68). This multiplicity of signals in a region notable for complex imprinting effects, and several strong biological candidates (INS, IGF2, KCNQ1, and CDKN1C), illustrates a previously unrecognized degree of complexity in the risk-variant architecture at this locus.
The effects of BMI and sex. At most T2D loci, there were only minimal differences in the estimated T2D effect sizes between BMIadjusted and unadjusted models (Methods and Fig. 2) . However, at index SNPs for 41 signals (mapping to 21 known and 16 novel loci), we observed significant differences in effect sizes between BMIadjusted and unadjusted analyses (P diff < 0.00012, corrected for 403
Full lists of authors and affiliations appear at the end of the paper. variants; Methods, Supplementary Table 3 and Fig. 2 ). This effectsize heterogeneity followed two distinct patterns. At 26 signals, including index variants for signals at the FTO, MC4R, TMEM18, SEC16B, and GNPDA2 loci, BMI adjustment produced marked attenuation of associations detected in unadjusted analysis. These signals displayed positive correlations between BMI and T2D effect sizes and represented T2D-risk effects driven primarily by adiposity. The other 15 signals were more strongly associated in the BMIadjusted analysis and reflected a mixture of associations, some with a marked effect on insulin secretion (for example, TCF7L2, ARAP1, and JAZF1), and others likely to influence T2D risk through a decreased capacity for fat storage in peripheral adipose tissue 11 (for example, GRB14, PPARG, HMGA1, and ZNF664).
In a comparative analysis of T2D effects in males (41,846 cases and 383,767 controls) and females (30,053 T2D cases and 434,336 controls; Methods) 12 , only one of the 403 T2D signals showed significant (P diff < 0.00012) differences in effect size (rs2925979 near CMIP, female OR = 1.09, male OR = 1.03, P diff = 8.3 × 10 Table 4) . We observed nominally significant differences at several other loci, including KLF14 (rs1562396, female OR = 1.09, male OR = 1.04, P diff = 0.00048), at which there is additional corroboration for sex-specific effects 13, 14 , thus indicating that additional examples of sex-differentiated signals are likely to be found in larger samples.
Fine-mapping variants driving T2D-association signals.
Previous efforts to fine-map causal variants within T2D loci have been hampered by both biological (extensive LD) and technical (diverse genotyping scaffolds or incomplete reference panels) factors. We sought to establish the extent to which the combination of increased sample size, an enlarged reference panel, and harmonized variant quality control would enhance fine-mapping resolution. We were able to undertake fine-mapping for 380 of the 403 distinct T2D-association signals, after conditional decomposition of loci with multiple signals (Methods). For each, we constructed credible sets that collectively accounted for ≥ 99% of the PPA (Methods) 15 . These credible sets included a median of 42 variants (range 1-3,997; Supplementary Fig. 2 ) and spanned a median of 116 kb (range 1 bp-995 kb). At 51 signals, involving 44 loci (18 novel), the most strongly associated variant accounted for > 80% PPA (Fig. 3 and Supplementary Table 5) . At 18 signals, the credible set included a single variant (PPA > 99%).
We explored the fine-mapping resolution at 83 distinct signals for which detection in both studies allowed us to compare 99%-credible sets from the HRC-based analysis with those constructed in a subset of these T2D GWAS imputed by the 1000 Genomes Project (1000G) multiancestral reference panel 1 (26,676 T2D cases; 132,532 controls of European ancestry, N eff 72,143). Although the former includes 2.3-fold more variants genome wide than the latter, the HRC-imputed analysis resulted in smaller credible sets. The median number of variants at these 83 signals decreased from 59 to 10, and the interval length decreased from 60.3 kb to 19.2 kb. At 79 of 83 signals, HRC-based credible sets were either smaller than those generated from 1000G or unchanged (Fig. 4 and Supplementary Table 6 ).
This improved resolution probably reflects the combination of (i) increased N eff ; (ii) improved imputation quality, especially for lower-frequency variants 4 ; and (iii) more effective, harmonized, quality control across contributing studies (Methods). To estimate the contribution to fine-mapping resolution attributable to the increase in N eff (the other factors are more difficult to tease apart), we constructed 99%-credible sets by downscaling the HRC imputation to a subset of 19 studies (31,387 cases and 326,742 controls, N eff 92,960) that contributed to both 1000G and HRC-based analyses. Among 41 single signal loci with P < 1 × 10 −5 in this downscaled meta-analysis, estimates of the credible-set size (median 66) and interval (median 196 kb) indicated that the improvements in causalvariant resolution derived mostly from increased sample size.
The HRC panel provides excellent coverage of all but very rare single-nucleotide variants. However, one HRC limitation is the absence of indels, which constitute 4% of total variants in the phase 3 1000G reference panel 16 . We considered the 245,207 indels from the European subset of the 1000G panel that mapped within 500 kb of the index variants at the 380 fine-mapped signals: these accounted for 2.8% of variants across the 380 Mb of sequence. Only 1% of these were in even moderate LD (r 2 > 0.5) with index variants for each T2D-association signal, thus indicating that indel omission probably had a limited effect on our estimates of credible set size.
The contribution of lower-frequency variants. The limited yield of low-frequency and rare-variant signals in previous T2D GWAS placed an upper bound on their individual and collective contributions to disease risk 17 . The present analysis, with a larger sample size and improved imputation, provided greater power in this regard, identifying 56 low-frequency and 24 rare T2D-associated variants across 60 loci (Fig. 5) . Six of these 80 signals mapped within known T2D loci, and five reconfirmed earlier observations (Supplementary Table 2 ).
The allelic OR for low-frequency and rare variants ranged from 1.08 to 8.05 (including 14 with estimated allelic OR > 2; at each, the minor allele conferred T2D risk), compared with 1.03-1.37 for common variants (Fig. 5) . The 80 lower-frequency risk variants cumulatively explained 1.1% of phenotypic variance in T2D, compared with 16.3% attributable to the 323 common-variant signals (Methods). Extrapolation beyond these discovered signals to estimate the full contribution of lower-frequency variants to T2D risk is intrinsically difficult, given the combination of effect-size overestimation and limited power to capture lower-frequency variants of lesser effect. Nonetheless, these data are consistent with recently proposed models for the genetic architecture of T2D based on GWAS and sequencing data 17 . Notwithstanding, the identification of lower-frequency variants with modest-to-large effects can provide valuable biological inference. Below, we briefly describe some of these signals.
We observed a mix of common-variant and low-frequency-variant signals around NEUROG3, including T2D risk attributable to the minor alleles at rs41277236 (p.Gly167Arg, MAF = 4.3%, OR = 1.09, P = 1.5 × 10 ) and rs549498088 (noncoding, MAF = 0.60%, OR = 1.56, P = 4.7 × 10
−7
). NEUROG3 encodes the neurogenin-3 transcription factor, which has been implicated in pancreatic islet and enteroendocrine cell development 18 . Rare homozygous, hypomorphic missense mutations in NEUROG3 (nonoverlapping with those that we detected) are a cause of childhood-onset diabetes associated with severe malabsorptive diarrhea 19 . The age of T2D diagnosis among carriers of these low-frequency T2D-risk alleles was, in the UK Biobank, similar to that among noncarriers (rs41277236: 52.3 versus 52.7 years, P = 0.21; rs549498088: 51.1 versus 52.7 years; P = 0.49), indicating a spectrum of phenotypes associated with NEUROG3 variants that extends to typical T2D. In the UK Biobank, T2D-risk alleles at NEUROG3 were associated with phenotypes recapitulating the gastrointestinal component of the neonatal syndrome (including 'obstruction of bile duct' (OR = 1.29; P = 0.023), 'gastrointestinal complications' (OR = 1.79; P = 0.024), and 'functional digestive disorders' (OR = 1.06; P = 0.027)).
We detected two previously unreported rare alleles with large ORs. The first was intronic to DENND2C (rs184660829, MAF = 0.020%, OR = 8.1, P = 2.5 × 10
−8
). In exploratory analyses within UK Biobank, the T2D-risk allele was associated with 'lower gastrointestinal congenital anomalies' (OR = 17.3 P = 0.00047). The second allele mapped near KIF2B (rs569511541, MAF = 0.020%, OR = 7.6, P = 1.5 × 10 −8
) and was also associated with 'congenital anomalies of endocrine gland' (OR = 30.8; P = 0.00015), 'disease of pancreas' (OR = 5.9; P = 0.0017), and 'hypokalemia' (OR = 6.9; P = 0.0046). Both sites are present in the Genome Aggregation Database 20 and met quality-control criteria in our data (average imputation quality > 0.7; association signal visible in multiple studies), but their precise contribution to T2D risk requires further validation.
Causal coding variants.
We next considered the 51 signals (of 380) for which fine-mapping strongly implicated (PPA > 80%) a single causal variant. Eight of these were missense coding variants, six of which were within established T2D-associated regions (Supplementary Table 7 ). With the exception of p.Cys130Arg at APOE (MAF = 15.4%), all have been implicated as causal for T2D: p.Ser539Trp in PAM (MAF = 0.83%); p.Thr139Ile in HNF4A (MAF = 3.5%); p.Asp1171Asn in RREB1 (MAF = 11.3%); p.Ala146Val in HNF1A (MAF = 2.9%); and p.Pro446Leu in GCKR (MAF = 39.3%) 3 . Coding-variant associations at PATJ (p.Gly157Val; 9.5% MAF) and CDKN1B (p.Val109Gly; 23.5% MAF) are novel and highlight these genes as playing direct roles in T2D risk. PATJ is highly expressed in the brain 21 and encodes Pals1-associated tight junction component, a protein with multiple PDZ domains, which mediate protein-protein interactions. Associations for this variant indicated a central mechanism of action: the T2D-risk allele was associated with obesity in the UK Biobank (OR = 1.11; P = 3.8 × 10 ), and the T2D-association signal was attenuated in BMI-adjusted analysis (P diff = 9.3 × 10
−10
). CDKN1B encodes a cyclin-dependent-kinase inhibitor, and deletion of this gene in mice ameliorates hyperglycemia by increasing islet mass and maintaining compensatory hyperinsulinemia 22 . There were four further signals (at ANKH, POC5, NEUROG3, and ZNF771) at which a single missense variant accounted for most (> 50%) of the PPA (Supplementary Table 7 ).
Integration of regulatory annotations to support fine-mapping. Of the 51 variants with PPA > 80%, 43 mapped to regulatory sequence: 12 of these were low frequency or rare, including variants near ANKH, CCND2, and WDR72. To characterize the regulatory effects of these 51 variants, we overlaid them onto chromatin-state maps from T2D-relevant tissues (islets, liver, adipose, and skeletal muscle [23] [24] [25] ) and transcription-factor-binding sites 23, 24 . Twenty-eight mapped to islet enhancer or promoter elements; for 14, these chromatin states were islet specific (Supplementary Table 8 and Supplementary Fig. 3 ). These data recapitulate previous findings implicating islet regulatory mechanisms at the CDC123-CAMKD1 (rs11257655) and MTNRB1 (rs10830963) [25] [26] [27] loci, and indicate that similar molecular mechanisms operate at signals for several other known T2D loci, including IGF2BP2, ANK1, GLIS3, CDKN2B, KCNQ1, CCND2, and BCL2A. Novel T2D signals near ABCB10, FAM49A, LRFN2, CRHR2, and CASC11 also overlapped islet-specific enhancers or promoters. High-PPA variants (i.e., those with PPA > 80%) at 13, 10, and 7 signals overlapped enhancers or promoters in adipose, skeletal muscle, and liver tissues, respectively. All but four of these were also enhancers or promoters in islets: one signal (near GLI2) mapped to an adipose-specific enhancer, another (near WDR72) mapped to a liverspecific enhancer, and two (near PTGFRN and TSC22D2) mapped to enhancers in both adipose tissue and skeletal muscle.
We next evaluated whether the integration of genome-wide-regulatory annotation data could refine the mapping resolution at those loci where genetic fine-mapping was less precise 25 . We focused on regulatory annotations from human islets because (i) most established T2D-risk variants are considered, given observed patterns of association with continuous metabolic traits, to act through primary effects on beta-cell function 3, 28, 29 ; (ii) the strongest signal for regulatory enrichment at T2D-association signals involves isletspecific regulatory elements 23, 26 , a view supported by the annotation overlaps of the high-PPA variants described above and by enrichment analyses that we performed using epigenomic annotations from islets, fat, muscle, and liver 24 ( Supplementary Fig. 4) ; and (iii) we had access to high-resolution epigenomic and chromatinstate annotation maps for human islets combining available data on histone modifications, transcription-factor binding, chromatin accessibility, and whole-genome methylation 25 . Using the hierarchical modeling approach fGWAS 30 , we observed strong (1.9-to 8.2-fold), significant (95% confidence not overlapping one), genome-wide enrichment of T2D-associated variation with respect to multiple islet enhancer and promoter states, as well as coding sequence (with concomitant depletion of heterochromatin states; Methods and Supplementary Fig. 5 ). We used the parameter estimates from the joint annotation model (which retained islet enhancers, promoters, and coding sequence, among other annotations; Methods and Supplementary Fig. 5 ) as priors to redefine 99%-credible sets for the 380 distinct T2D-association signals amenable to fine-mapping. We circumvented the default assumption in fGWAS of a single casual variant per locus by conducting these analyses on conditionally decomposed data (noting that this procedure still allowed for the possibility that the association at each conditional signal might be distributed across multiple variants on a risk haplotype; Methods). The number of variants included in the 99%-credible set for each of the 83 distinct signals constructed through meta-analysis of GWAS data imputed from the 1000G multiancestry reference panel (26,676 T2D cases and 132,532 controls) (x axis; logarithmic scale) is plotted against those (y axis; logarithmic scale) derived by HRC-based imputation (74,124 T2D cases and 824,006 controls). The inset presents the same plot but with linear scales.
As expected, this integrated fine-mapping analysis boosted PPA for variants overlapping enriched annotations (Fig. 6 ). The median 99%-credible-set size declined from 42 to 32, the credible intervals declined from 116 kb to 100 kb, and the maximum variant PPA per signal increased by a median of 21%. The number of signals at which the lead-variant PPA exceeded 80% increased from 51 to 73, and there were dramatic improvements at some (for example, at GNG4, for which the PPA for rs291367 rose from 24.0% to 84.2%; Fig. 3) .
These annotation-supported analyses highlighted seven additional loci (beyond the 12 determined from genetic evidence alone) where most (> 50%) of the PPA was based on a coding variant (Supplementary Table 7 ). Four were novel: QSER1 (p.Arg1101Cys; MAF = 4.3%), SCD5 (p.Glu197Gln, MAF = 33.8%), IRS2 (p.Gly1057Asp, MAF = 34.0%), and MRPS30 (p.Glu128Gln = MAF 2.8%).
In our recent study of exome-array genotypes, we demonstrated that, for one-third of loci with coding-variant associations, a causal role could be excluded after information on local LD and annotation enrichment was incorporated 3 . For all 19 coding-variant signals (at 18 loci) described in this study, the results of the present analyses (based on genome-wide data for both discovery and finemapping) were consistent with a causal role. These analyses therefore provide additional examples of human validated targets 31 . The value of these targets as leads for therapeutic development will ultimately depend not only on their effects on T2D phenotypes but also on the consequences of perturbation on other traits, including coronary artery disease (CAD). Among the 19 T2D-associated coding variants, nine were also nominally associated (P < 0.05) with CAD 32 : for three variants (APOE, GCKR, and RREB1), opposing effects on T2D and CAD predisposition render them less attractive targets (Supplementary Table 7) .
Next, we concentrated on noncoding-variant signals. In the annotation-informed analysis, we identified 15 additional signals (beyond the 43 noncoding signals described above) for which the lead-variant PPA exceeded 80% (Supplementary Table 8 ). These signals overlapped active islet regulatory sites including strong enhancers (for example, at TCF7L2, HNF4A, ANKH, RNF6, and ZBED3), active promoters (EYA2), weak enhancers (ADSCL2, ADCY5, CDKN2B, and TBCE), and weak promoters (DGKB). For many signals, the data (for example, associations with continuous metabolic traits 3, 28, 29 and cis expression quantitative trait locus (eQTL) data 33 ; Supplementary  Table 8) were consistent with a role in islet function. In contrast, for six signals, including three that are likely, on physiological grounds, to act at least partly through effects on islets, we observed decreases (10% to 76%) in the lead-variant PPA after islet-annotationinformed fGWAS (Supplementary Table 8 ). This decrease occurred when lead variants from the genetic fine-mapping overlapped with annotations depleted in the genome-wide model. Examples included variants at primary CDKAL1 and secondary KCNQ1 and INS-IGF2 signals, where the index-variant PPA decreased by 76% (rs7756992), 34% (rs2283164), and 22% (rs555759341), respectively. One possible explanation for these results is that for these T2D-association signals, the phenotypic effect on insulin secretion may be mediated through long-term consequences of regulatory effects during islet development, which are no longer reflected in the regulatory annotations seen in mature islets.
At many of these fine-mapped regulatory loci, the integrated data provided novel insights into disease mechanisms, three of which are highlighted below. At ST6GAL1, rs3887925 achieved PPA = 98.5% through genetic fine-mapping alone (99.3% in fGWAS), and overlapped with enhancers active in islet, as well as liver, adipose, and skeletal muscle tissues (Supplementary Fig. 6 ). However, the T2D-risk allele at rs3887925 was associated with an increase in ST6GAL1 cis expression specific to islets 33 (Methods and Supplementary Table 8 ), in agreement with evidence of decreased insulin secretion in risk-allele carriers during provocative testing 34 . The candidate effector transcript ST6GAL1 encodes β -galactoside α 2,6-sialyltransferase-1, a key enzyme responsible for the biosynthesis of α 2,6-linked sialic acid in N-linked glycans. Altered glycosylation has the potential to affect multiple processes, and global perturbation of ST6GAL1 has broad effects including, in St6gal1-knockout mice, increased body weight and visceral fat accumulation 35 . However, no equivalent association between rs3887925 and anthropometric and lipid phenotypes has been seen in human GWAS 14, 36, 37 . These results are consistent with the T2D predisposition attributable to rs3887925 being mediated through regulatory mechanisms restricted to the modulation of ST6GAL1 expression in islets.
At ANK1, we observed three distinct association signals. The strongest causal-variant attribution was for the primary signal at rs13262861 (PPA = 97.3% on the basis of genetic data alone; 98.8% with fGWAS). This variant overlaps an islet promoter located 3′ to ANK1 and 5′ to the transcription-factor-encoding NKX6-3 ( Supplementary Fig. 7 ). The T2D-risk allele at rs13262861 showed a directionally consistent association with in vivo measures of decreased insulin secretion 3, 29, 34 and a cis-eQTL for decreased NKX6-3 expression in human islets (Supplementary Table 8 ). Members of the NKX6 family (including NKX6.3) have been implicated in islet development and function 38 . A recent study has highlighted the relationship between variants including rs515071 and rs508419 and the expression and splicing of ANK1 in skeletal muscle 39 . However, in our meta-analysis, variants influencing ANK1 splicing had a minimal effect on T2D risk (PPA < 1% in all three conditionally decomposed signals (genetic fine-mapping only)). Collectively, these data indicate that the mechanism of T2D predisposition at this locus is probably mediated through decreased islet expression of NKX6-3 rather than altered muscle expression of ANK1.
At TCF7L2, patterns of overlap with epigenomic annotations across the eight distinct T2D-association signals offered explanations for the diverse metabolic consequences of TCF7L2 perturbation in humans and animal models 40 (Supplementary Table 9 ). The primary signal at rs7903146, long established as the largest commonvariant effect for T2D in Europeans, overlapped an islet enhancer (boosting PPA from 59.2% to 97.1% in fGWAS), multiple islet-relevant transcription-factor-binding sites, and islet open chromatin 41 , features consistent with the islet phenotype (deficiency in insulin secretion) evident in nondiabetic individuals 7 ( Supplementary  Fig. 8 ). However, among the seven secondary signals, the picture was more mixed. Of the four secondary signals mapped to fewer than ten credible-set variants, only rs144155527 rose to moderate PPA (68%) after islet-annotation-enriched fGWAS analysis. Other credible-set variants mapped to adipose and liver enhancers, thus suggesting that their T2D-risk effects are mediated via modulation of TCF7L2 expression in tissues relevant to insulin action.
Heritability estimates and polygenic-risk-score prediction.
Using LD-score regression 42 , and empirical estimates of populationand sample-level T2D prevalence, we estimated the chip heritability (on the liability scale) for T2D at 18% (23% in females and 17% in males; Supplementary Fig. 9 ), accounting for approximately half the median estimates of heritability derived from twin and family studies 43 . Identification of individuals at increased genetic risk for T2D may enhance screening strategies and allow for targeted prevention. Previous attempts to deploy genetic data for disease prediction have shown limited utility 44, 45 . We used a revised BMI-unadjusted meta-analysis, generated from all samples other than the UK Biobank samples, to develop genome-wide polygenic risk scores (PRSs) 46 , which we then applied to predict T2D status in the 18,197 cases and 423,697 controls from the UK Biobank (Europeans only; Methods) 46 . Maximal discrimination (area-under-the-curve C statistic of 66%, equivalent to that derived from BMI, age, and sex in the same sample) was obtained from a PRS of 136,795 variants (r 2 > 0.6, P < 0.076; Supplementary Fig. 10 ). Individuals in the top 2.5% of the PRS distribution were at 3.4-fold-increased risk (prevalence = 11.2%) compared with the median (prevalence = 3.3%), and at 9.4-fold-increased risk compared with the bottom 2.5% (prevalence = 1.2%). Low T2D prevalence in the UK Biobank reflected the age distribution of the cohort and preferential ascertainment of healthy individuals; however, similar prevalence ratios were observed in the subset of individuals > 55 years of age at recruitment (14.2% versus 1.6%). If applied to the general UK population, an equivalent performance would equate to lifetime T2D risks of ~59.7% and ~6.7% for individuals from those extremes, on the basis of current UK general-population prevalence rates for individuals > 55 years of age 47 .
Defining relationships with other traits.
To characterize genetic relationships with other biomedically relevant traits, we used LD-score regression 42 implemented in LDHub 48 . We tested 182 unique phenotypes after excluding those with low heritability estimates and repeated measures. Eighty-five traits demonstrated a significant (Bonferroni-corrected threshold P < 0.00027) genetic correlation with T2D (Supplementary Table 10 and Supplementary Fig. 11 ).
These results highlighted several interesting genetic correlations, linking increased T2D risk to sleeping behaviors (insomnia and excessive daytime sleeping), smoking (cigarettes smoked per day, and having ever versus never smoked), metabolites (glycoprotein acetyls, isoleucine, and valine), depressive symptoms, urinary albumin-to-creatinine ratio, and urate. T2D risk was negatively correlated with anorexia nervosa, intelligence, parents' ages at death, lung-function measures, education status/duration, age at menarche, and age of mother at first childbirth. Many of these relationships (including those related to intelligence, smoking behavior, age at menarche, and education status) were primarily mediated by the shared effects of BMI on both T2D and the correlated phenotype ( Supplementary Fig. 12 ).
Discussion
This study demonstrates how substantial increases in sample size coupled to more accurate and comprehensive imputation can expand characterization of the genetic contribution to T2D risk. The number of significantly associated genomic regions doubled, and the harvesting of lower-frequency risk alleles, some with relatively large effects, increased. At many of these signals, finemapping resolution was substantially improved: we mapped 51 of 380 signals to single-variant resolution on the basis of genetic evidence alone and demonstrated that the integration of genomic annotations (here with a focus on the human islet epigenome) provided further specification of plausible causal variants. We highlight 18 genes as human-validated targets based on causal coding variants and provide novel insights into the biological mechanisms operating at several fine-mapped regulatory signals. These findings suggest mechanistic hypotheses that can now be targeted for large-scale empirical validation at the level of both variants (for example, through massively parallel reporter assays) and candidate effector genes (for example, through CRISPR screens in appropriate cellular models and manipulation in in vivo models). The present study was limited to individuals of European ancestry: integration of these data with large-scale GWAS data from other major ancestral groups (as is being pursued by the DIAMANTE consortium) should provide an additional boost to locus discovery and support further increases in causal-variant resolution, most obviously at loci where extensive LD within Europeans limits the resolution of fine-mapping. 
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Where β BMI and β noBMI are the estimated genetic effects from models with and without BMI adjustment, SE(β) is the estimated standard error of the estimates, and ρ = 0.89, is the estimated correlation between β BMI and β noBMI across all variants 1 .
Detection of distinct association signals.
We used GCTA 56 to perform approximate conditional analyses to detect distinct association signals at each of the genome-wide-significant risk loci for T2D (newly identified or confirmed, except at the major histocompatibility complex (MHC) region). GCTA performs conditional analysis using association summary statistics from GWAS metaanalysis and estimated LD from a sufficiently large reference study used in the meta-analysis. We used a reference sample of 6,000 (nearly) unrelated (pairwise relatedness < 0.025) individuals of white British origin, randomly selected from the UK Biobank, to model patterns of LD between variants. The reference panel of genotypes consisted of the same 39 million variants from the HRC reference panel assessed in our GWAS, but with an additional quality-control step to exclude SNPs with low imputation quality (proper info < 0.4) or deviation from Hardy-Weinberg equilibrium (P < 1 × 10
−6
). For each locus, we first searched ± 500 kb surrounding the lead SNP (using summary statistics from BMI-unadjusted or adjusted analysis, as appropriate) to ensure that potential long-range genetic influences were assessed. Within a region, conditionally independent variants that reached locus-wide significance (P < 10
) were considered as index SNPs for distinct association signals. If the minimum distance between any distinct signals from two separate loci was less than 500 kb, we performed additional conditional analysis including both regions (encompassing ± 500 kb from both ends) and reassessed the independence of each signal.
Fine-mapping of distinct association signals with T2D susceptibility. We considered 380 of the 403 identified distinct signals, excluding 23 that were not amenable to fine-mapping: (i) 19 signals with MAF < 0.25%; (ii) three signals for which the index variant was rare and analyzed in < 50% of the total effective sample size, defined as N e = 4 × N cases × N controls /(N cases + N controls ); and (iii) the one signal in the major histocompatibility complex because of the extended and complex structure of LD across the region, which complicates fine-mapping.
For each of the remaining distinct signals, we first defined a genomic region 500 kb on either side of the index variant, considering only variants with MAF > 0.25% that were reported in at least 50% of the total effective sample size, thus removing those that were not well imputed in most samples. We then adopted two approaches to compute 99%-credible sets with a 99% posterior probability of containing the causal variant: (i) using a (functionally unweighted) Bayesian approach, with the strength of evidence for association measured with the Bayes' factor in favor of association for each variant 15, 57 ; and (ii) using (functionally weighted) fGWAS 30 that reweights the association measures using information from functional genomics data.
Genetic credible sets. For each distinct association signal, we first calculated an approximate Bayes factor 57 in favor of association on the basis of allelic effect sizes and standard errors from the meta-analysis (using BMI-unadjusted or BMIadjusted meta-analysis, as appropriate). For loci with a single association signal, effect sizes and standard errors from unconditional meta-analysis were used. For loci with multiple distinct association signals, these parameters were derived from the approximate conditional analysis, with adjustment for all other index variants in the region. Specifically, for the jth variant,
where β j and V j denote the estimated allelic effect (log OR) and corresponding variance from the meta-analysis. The parameter ω denotes the prior variance in allelic effects, taken here to be 0.04 (ref. 57 ). We then calculated the posterior probability that the jth variant drives the association signal (PPA), given by
The 99%-credible set 15 for each locus was then constructed by (i) ordering all variants in descending order of their PPA; and (ii) including ordered variants until the cumulative PPA reached 0.99. The number of variants and length of the genomic region covered by each 99%-credible set was then calculated.
Functionally weighted credible sets. We first tested each of the 15 chromatin states in human islets and coding DNA sequence separately for enrichment using genome-
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Ethics statement. All human research was approved by the relevant institutional review boards and conducted according to the Declaration of Helsinki. All participants provided written informed consent.
Study-level analyses.
We considered a total of 74,124 T2D cases and 824,006 controls from 32 GWAS undertaken in individuals of European ancestry (Supplementary Table 1) , genotyped with a variety of genome-wide SNP arrays. Sample and variant quality control were performed within each study (Supplementary Table 1 ). To improve the quality of the genotype scaffold in each study, we developed a harmonized protocol in which variants were subsequently removed if (i) allele frequencies differed from those for European-ancestry haplotypes from the HRC reference panel 4 by more than 20%; AT/GC variants had MAF > 40% because of potential undetected errors in strand alignment; or (iii) MAF < 1% because of difficulties in calling rare variants (with exception of BioMe, MGI, and UPCH, for which no MAF exclusion was implemented, because genotyping was performed with newer GWAS arrays; Supplementary Table 1) . Each scaffold, with the exception of the deCODE GWAS, was then imputed up to the HRC reference panel 4 . The GWAS from deCODE was imputed up to a reference panel based on 30,440 Icelandic whole-genome sequences 5 , and only variants that were present in the HRC panel were considered for downstream analyses. Within each study, all variants were tested for association with T2D in a regression framework, with and without adjustment for BMI, in sex-combined and sex-specific analyses, under an additive model of the effect of the minor allele, with additional adjustment for study-specific covariates (Supplementary Table 1 ).
To account for population structure and relatedness, association analyses were either adjusted for principal components (after exclusion of related individuals) or implemented in a mixed model with random effects for kinship from a geneticrelationship matrix. For studies analyzed with linear mixed models, implemented in EMMAX 49 or BOLT-LMM 50 (Supplementary Table 1 ), allelic effects and standard errors were converted to the log-odds scale to correct for case-control imbalance 51 . For each analysis, in each study, variants were removed from a study if (i) minor allele count < 5 (in cases and controls combined); (ii) imputation quality ř 2 < 0.3 (miniMAC) or proper info < 0.4 (IMPUTE4); or (iii) standard error of the allelic log OR > 10. The association summary statistics for each analysis within each study were then corrected for residual structure by means of a genomic-control inflation factor 52 , calculated after exclusion of variants mapping to established T2D-susceptibility loci (Supplementary Table 1 ).
Sex-combined meta-analysis. We aggregated association summary statistics from sex-combined analyses for each variant across studies, with and without adjustment for BMI, using fixed-effects meta-analysis with inverse-variance weighting of log ORs, as implemented in METAL 53 . The BMI-unadjusted meta-analysis was subsequently corrected for residual inflation (to account for structure between studies) by means of genomic control (λ = 1.013) (ref. 52 ), calculated after the exclusion of variants mapping to established T2D-susceptibility loci. No adjustment was required for the BMI-adjusted meta-analysis (λ = 0.992). From the metaanalysis, variants were extracted that passed quality control in at least two studies. Heterogeneity in allelic effect sizes between studies contributing to the meta-analysis was assessed with Cochran's Q statistic 54 . We defined novel loci as those mapping > 500 kb and conditionally independent from a previously reported lead GWAS SNP.
In the present study, we maintained the conventional genome-widesignificance threshold of 5 × 10 −8
, for compatibility with previous reports. We recognize that more comprehensive capture of lower-frequency variants in particular increases the effective number of tests and consequently increases the false-positive rate for signals just below this threshold. 162 of the 243 primary signals were significant at a more stringent threshold (5 × 10 ) recently advocated for whole-genome-sequence data 55 , and the major conclusions of the manuscript remained unchanged when we selected this more stringent (and, given that our data lacked the full coverage of WGS data, overconservative) threshold. All summary-level data results are available so that readers can interpret the results themselves.
With our sample size (N eff 231,436), assuming accurate imputation (imputation quality score > 0.8), we had > 80% power to detect T2D association (at α = 5 × 10 Sex-differentiated meta-analysis. The meta-analyses described above were repeated for males and females separately, and correction was performed for population structure by genomic control as necessary: (i) male-specific BMIunadjusted λ = 1.029; (ii) male-specific BMI-adjusted λ = 1.001; (iii) female-specific BMI-unadjusted λ = 0.955; and (iv) female-specific BMI-adjusted λ = 0.932. The male-specific meta-analysis consisted of up to 41,846 cases and 383,767 controls, whereas the female-specific meta-analysis consisted of up to 30,053 cases and 434,336 controls. The sex-specific meta-analyses were then combined to conduct a sex-differentiated test of association and a test of heterogeneity in allelic effects between males and females 12 .
Assessment of effects of BMI adjustment. We compared the genetic effect sizes (beta coefficients) estimated from models with and without BMI wide data with the program fGWAS 30 . Details on generation of the 15 chromatin states have been described elsewhere 25 . The annotation with the most significant enrichment was retained and tested jointly with each remaining annotation. If the most significant two-annotation model improved the model likelihood then the two annotations in the model were retained, and the process continued until the model likelihood did not exceed the previous iteration. The resulting 'full' model was iteratively pruned by dropping each annotation and assessing the crossvalidated likelihood of the reduced model (i.e., an annotation was removed from the full model if dropping it increased the cross-validated likelihood). This process resulted in the 'best joint model' .
By default, fGWAS partitions the genome into 'blocks' of 5,000 SNPs and assumes no more than one causal variant per block. However, for direct comparison with the 'genetic' credible sets and to account for multiple distinct association signals within a locus, we used a modified approach. For T2D-associated regions with no evidence of more than one distinct signal, we delineated 1-Mb windows comprising all SNPs within 500 kb of the index variant and partitioned the intervening regions into ~1-Mb windows. These windows were manually input into fGWAS with the --bed command, and a separate fGWAS analysis was performed with only the set of annotations remaining in the best joint model. The genome-wide enrichments were used as priors in a Bayesian fine-mapping analysis implemented in fGWAS to calculate posterior probabilities for each SNP in the designated windows. For the remaining regions with evidence of two or more distinct association signals, we used the results from the approximate conditional analyses described above and similarly performed a manually partitioned fGWAS analysis. We then constructed 99% credible sets as described above.
Association analyses with UK Biobank phenotypes. We performed targeted association analyses using genotype and phenotype data from electronic health records (EHRs) from the UK Biobank. Hierarchical phenotype codes from EHRs were curated by grouping International Classification of Disease, Ninth Revision (ICD-9) clinical/billing codes as previously described 58 . Only phenotype codes with 20 or more cases and with a minor-allele count ≥ 5 in cases and controls were considered eligible for analysis. Logistic-regression analyses were performed in individuals of European ancestry for relevant phenotype-genotype combinations by adjusting for six genetic-ancestry principal components, array, and sex.
For NEUROG3, we tested 12 specific phenotypes that capture gastrointestinal components of the syndrome from more severe mutations in the gene, and we report nominal association without any correction for multiple testing (but we note that the various diagnoses have a complex nested, correlation structure). For the two novel rare variants, we interrogated 52 endocrine/digestive phenotypes and again found a nominal association without any correction for multiple testing.
Estimating phenotypic variance explained by SNPs. We used UK Biobank samples (19,119 T2D cases and 423,698 controls) to calculate the variance explained by genome-wide-significant variants. We ran a model regressing T2D status on all independently associated rare and low-frequency variants, assuming an additive model (and adjusting for sex, age, array, and six principal components). A separate model was run to determine the variance captured by the independently associated common variants.
Colocalization analysis. We used publicly available eQTL results from GTEx version 7 for adipose, liver, and skeletal tissues. Islet eQTLs were called using published imputed genotypes and aligned RNA-seq data (.vcf and .bam files) from human pancreatic islets of 118 individuals, downloaded from the European Genome-phenome Archive (accession number EGAS00001001265). RNA extraction, sequencing, and mapping, as well as DNA extraction, genotyping, imputation, and variant filtering were performed as previously described 33 . Genelevel reads were quantified with featureCounts version 1.5.0-p2 (ref. 59 ), on the basis of a patched version of GENCODE 19 published by the GTEx Consortium. Quantified gene-level read counts for pancreatic islets were filtered in line with protocols used for GTEx version 7: only genes with at least six raw counts in 20% of the samples and TPM > 0.1 in at least 20% of the samples were used for analysis. Gene-level counts for remaining genes were converted to counts per million, library sizes were normalized in edgeR version 3.16.5 (ref. 60 ), and the resulting expression values were rank inverse normalized per gene. Fifteen PEER factors 61 were calculated, and cis-eQTLs were called with FastQTL version 2.0 (ref. 62 ) using a cis distance of 1 Mb and PEER factors as covariates.
We performed colocalization analysis in eCAVIAR version 2.0 (ref.
63
). Colocalization was performed for each locus-tissue pair using genetic-credible-set variants from the locus that had (i) PPA > 0.01, (ii) correlation data from 1000G, and (iii) available eQTL results from that tissue. Pairwise variant correlations between credible-set SNPs were calculated with PLINK version 1.9 (ref. 
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